All the news Showing 10 of 56 articles from: Treatment outcomesGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Curing hepatitis C reduces liver-related complications and death Liz Highleyman / 23 January 2017 People with hepatitis C who achieve sustained virological response to treatment had lower liver-related morbidity and mortality rates compared to people who were not successfully treated, according to research presented at the 2016 ... Real-world studies show 8-week sofosbuvir/ledipasvir course just as effective as 12-week course for genotype 1 patients without cirrhosis Keith Alcorn / 02 December 2016 An 8-week course of treatment with sofosbuvir/ledipasvir is just as effective as a 12-week course of treatment in people without cirrhosis, including those with HIV/hepatitis C virus (HCV) co-infection, and could significantly reduce ... Real-world responses to HCV treatment among US veterans match best clinical trial results Keith Alcorn / 14 November 2016 Direct-acting antiviral (DAA) treatment is curing people of hepatitis C infection in clinics at similar rates to those seen in clinical trials, and there don’t seem to be major differences between drug regimens, ... AbbVie 3D regimen taken for 8 weeks cures almost all HCV genotype 1b patients without cirrhosis Liz Highleyman / 06 October 2016 AbbVie’s paritaprevir-based ‘3D’ regimen taken for just 8 weeks without ribavirin led to sustained virological response in 98% of easier-to-treat patients with hepatitis C virus (HCV) genotype 1b who did not have cirrhosis, ... 100% cure rate for people with HCV genotype 1 treated with AL-335, odalasvir and simeprevir for 6 or 8 weeks Liz Highleyman / 05 October 2016 A triple regimen containing two experimental hepatitis C drugs – AL-335 and odalasvir – plus simeprevir taken for either 6 or 8 weeks cured all participants with previously untreated genotype 1 hepatitis ... Risk of reinfection is a concern after successful hepatitis C treatment Liz Highleyman / 28 September 2016 People on opiate agonist substitution therapy can be successfully treated with grazoprevir/elbasvir (Zepatier) – achieving cure rates similar to those of the population as a whole – but some people are reinfected ... Successful hepatitis C treatment reduces portal hypertension and its complications Liz Highleyman / 27 June 2016 Direct-acting antiviral therapy for hepatitis C that produces a sustained virological response can lead to reduction in portal vein pressure, which causes some of the most serious complications of cirrhosis, according to a ... Low-cost generic hepatitis C drugs match branded products in viral responses Keith Alcorn / 16 April 2016 Generic versions of direct-acting antivirals purchased from China and India by people unable to obtain treatment in their own countries were just as effective and safe as the branded products, a study ... Clinical impact of effective HCV DAAs: referrals for liver transplant drop after their introduction Keith Alcorn / 04 December 2015 The number of hepatitis C virus (HCV)-related referrals for liver transplant has declined significantly since the introduction of HCV direct-acting antivirals (DAAs), according to two US studies presented to the recent 2015 ... Liver fibrosis improves after successful treatment for hepatitis C Liz Highleyman / 02 December 2015 A majority of people with chronic hepatitis C and advanced fibrosis or cirrhosis showed improvement in liver health following treatment, according to study findings presented last week at the 2015 AASLD Liver ... ← Prev1...23456Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive